SAB Biotherapeutics, Inc. (SABS)

Market Cap	34.15M
Revenue (ttm)	1.51M
Net Income (ttm)	-45.57M
Shares Out	9.23M
EPS (ttm)	-5.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	144,967
Open	3.260
Previous Close	3.260
Day's Range	3.260 - 3.740
52-Week Range	2.160 - 9.720
Beta	0.64
Analysts	Strong Buy
Price Target	12.40 (+235.14%)
Earnings Date	Nov 6, 2024

About SABS

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroen...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: SABS
• Website: https://www.sabbiotherapeutics.com

Financial Performance

In 2023, SAB Biotherapeutics's revenue was $2.24 million, a decrease of -90.63% compared to the previous year's $23.90 million. Losses were -$42.19 million, 125.1% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for SABS stock is "Strong Buy." The 12-month stock price forecast is $12.4, which is an increase of 235.14% from the latest price.

Price Target

$12.4

(235.14% upside)

Analyst Consensus: Strong Buy